Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 32 peer-reviewed journal articles Updated
Ophthalmology

What Are the New Treatments for Corneal Dystrophy?

At a Glance

While corneal transplants remain the standard of care, new corneal dystrophy treatments are emerging. These include ROCK inhibitor eye drops combined with Descemet Stripping Only (DSO), cultured cell injections, and experimental gene therapies targeting the genetic root of the disease.

Yes, there are exciting new treatments in development and early clinical use that aim to treat corneal dystrophies without requiring a traditional donor corneal transplant. While surgical transplants like DMEK (Descemet Membrane Endothelial Keratoplasty) or DSAEK (Descemet Stripping Automated Endothelial Keratoplasty) remain the standard of care for advanced disease [1], researchers are actively exploring specialized eye drops, cultured cell injections, and gene therapies. These innovations aim to preserve your native corneal tissue, clear abnormal deposits, and address the root genetic causes of the condition.

ROCK Inhibitor Eye Drops

Rho-kinase (ROCK) inhibitors, such as ripasudil and netarsudil, are eye drops currently approved for treating glaucoma, but they are increasingly being used “off-label” to manage Fuchs’ endothelial corneal dystrophy (FECD) [2][3]. Evidence shows that these drops stimulate corneal endothelial cells to multiply and migrate [4][5]. Because they are used off-label, they may not always be covered by insurance for this specific condition. Additionally, patients should expect side effects, most commonly significant eye redness (conjunctival hyperemia) [6].

ROCK inhibitors are most frequently used alongside a minimally invasive procedure called Descemet Stripping Only (DSO), also known as DWEK (Descemetorhexis Without Endothelial Keratoplasty) [7][8]. In DSO, the surgeon removes the central diseased layer of the cornea without putting a donor graft in its place [9]. The ROCK inhibitor eye drops then help the patient’s remaining healthy peripheral cells migrate to the center, clear the corneal swelling (edema), and improve vision [10][11].

This approach is best suited for patients who still have a healthy reserve of peripheral endothelial cells, which your doctor can measure using a special photograph of your eye called a specular microscopy or endothelial cell count [12][13]. It is important to know that DSO has a known failure rate; if the native cells fail to migrate and the cornea does not clear, the patient will eventually require a traditional DMEK or DSAEK “rescue” transplant [14][7].

Cultured Cell-Based Therapies

Instead of transplanting a full piece of donor tissue, scientists have developed ways to inject lab-grown human corneal endothelial cells directly into the eye [15][16]. In this therapy, cells from a single donor can be multiplied in a lab to treat dozens of patients, which could help solve the global shortage of donor corneas [17][18].

Because only pure cells are injected rather than a full tissue graft, early research suggests this approach may lower the long-term risk of graft rejection and reduce the need for chronic anti-rejection eye drops [17][19]. Once injected, the cells attach to the back of the cornea and rebuild the endothelial layer, restoring corneal clarity [20][21]. This process is often combined with ROCK inhibitors to help the injected cells survive and attach properly [22][23]. Clinical trials for these cultured cell therapies are actively underway and show promising early results for patients with endothelial dysfunction [24][20].

Gene Therapies (CRISPR and ASOs)

Because corneal dystrophies are genetic conditions, targeting the mutated genes is a major focus of research. Gene therapies aim to stop the production of the abnormal proteins that build up in the cornea.

  • For Fuchs’ Dystrophy: Researchers are targeting the TCF4 gene, which is the most common genetic driver of the disease [25][26]. In laboratory models, suppressing this gene helps prevent cell loss and the formation of the microscopic bumps (guttae) that characterize Fuchs’ dystrophy [25][27].
  • For TGFBI-related Dystrophies: For dystrophies like Granular or Lattice dystrophy, scientists are using gene editing tools like CRISPR/Cas9 to correct or silence the mutated TGFBI gene [28][29]. This aims to prevent the cloudy protein deposits from forming in the first place [29].

Currently, gene editing and antisense oligonucleotides (ASOs)—molecules designed to block specific genetic messages—remain in the preclinical, experimental stage for corneal dystrophies [30][31]. While they represent a highly anticipated future treatment avenue, there are currently no large-scale human clinical trials active for these specific gene therapies [30][32].

Because these potential genetic cures are likely still many years away from being widely available, patients experiencing active vision loss today should not delay proven, standard-of-care surgical treatments while waiting for gene therapy [1].

Common questions in this guide

What are ROCK inhibitor eye drops for Fuchs' dystrophy?
ROCK inhibitors are eye drops that doctors sometimes use off-label to help manage Fuchs' dystrophy. They work by stimulating your eye's remaining healthy corneal cells to multiply and migrate, which helps clear swelling and improve vision.
How does Descemet Stripping Only (DSO) work?
During DSO, a surgeon removes the diseased central layer of your cornea without inserting a donor graft. You then use specialized eye drops to encourage your own healthy outer cells to move to the center of your eye and restore clear vision.
What is cultured cell injection therapy for the eye?
Instead of a full tissue transplant, cultured cell therapy involves injecting lab-grown human corneal cells directly into the eye. These pure cells attach to the back of your cornea to rebuild the damaged layer, which may lower the risk of graft rejection.
Is gene therapy currently available for corneal dystrophy?
No, gene therapies like CRISPR are still in the experimental, preclinical stages for corneal dystrophies. If you are currently experiencing active vision loss, you should not delay proven standard-of-care surgical treatments while waiting for gene therapy to become available.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my peripheral endothelial cell count, and would I be a candidate for Descemet Stripping Only (DSO) with a ROCK inhibitor?
  2. 2.If I undergo DSO and it fails to clear my vision, what is the timeline for a 'rescue' traditional transplant?
  3. 3.Are there any active clinical trials at this institution or nearby for cultured cell injection therapies (such as the Aurion Biotech trials)?
  4. 4.Can we discuss the off-label use of ripasudil or netarsudil eye drops as a temporary measure to manage my corneal swelling?
  5. 5.Do you offer genetic testing for TCF4 expansions or TGFBI mutations, and how would that information impact my eligibility for future gene-based treatments?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

Related questions

Does Corneal Dystrophy Come Back After a Transplant?Can Diet or Lifestyle Changes Slow Corneal Dystrophy?Fuchs vs. Other Corneal Dystrophies: Key DifferencesWhy Does Corneal Dystrophy Cause Glare & Halos at Night?Does Corneal Dystrophy Affect Other Organs?Does Corneal Dystrophy Cause Blindness?How Often to See an Eye Doctor for Corneal DystrophyPartial vs. Full Corneal Transplant: What's the Difference?Should Family Members Be Tested for Corneal Dystrophy?What Are the RSVP Signs of Corneal Transplant Rejection?What Does a Recurrent Corneal Erosion Feel Like?Corneal Dystrophy vs Keratoconus: What's the Difference?Why Does Corneal Dystrophy Cause Morning Blurry Vision?Why is LASIK Contraindicated in Corneal Dystrophy?

References

References (32)
  1. 1

    Descemet Stripping Without Endothelial Keratoplasty in Early-Stage Central Fuchs Endothelial Dystrophy: Long-term Results.

    Vieira R, Castro C, Coelho J, et al.

    Cornea 2023; (42(8)):980-985 doi:10.1097/ICO.0000000000003131.

    PMID: 36731082
  2. 2

    A Close Look at the Clinical Efficacy of Rho-Associated Protein Kinase Inhibitor Eye Drops for Fuchs Endothelial Corneal Dystrophy.

    Kinoshita S, Colby KA, Kruse FE

    Cornea 2021; (40(10)):1225-1228 doi:10.1097/ICO.0000000000002642.

    PMID: 34481406
  3. 3

    Exploring the Role of ROCK Inhibition in Corneal Edema Through Crosstalk Between Epithelial and Endothelial Cells.

    Yi LY, Hsieh HH, Lin ZQ, et al.

    Journal of ophthalmology 2024; (2024()):9381303 doi:10.1155/2024/9381303.

    PMID: 39534682
  4. 4

    Magic Bullets: The Coming Age of Meaningful Pharmacological Control of the Corneal Responses to Injury and Disease.

    Wilson SE

    Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 2022; doi:10.1089/jop.2022.0088.

    PMID: 36161879
  5. 5

    Rho-Kinase Inhibitors in the Management of Fuchs Endothelial Corneal Dystrophy: A Review.

    Jukić A, Pupić Bakrač A, Đapic Ivančić B, et al.

    Medicina (Kaunas, Lithuania) 2025; (61(5)) doi:10.3390/medicina61050772.

    PMID: 40428730
  6. 6

    Reticular epithelial corneal edema as a novel side-effect of Rho Kinase Inhibitors: An Indian scenario.

    Bhargava M, Sen S, Bhambhani V, et al.

    Indian journal of ophthalmology 2022; (70(4)):1163-1170 doi:10.4103/ijo.IJO_2865_21.

    PMID: 35326007
  7. 7

    Descemet Stripping Only for Symptomatic Fuchs Endothelial Dystrophy-A Retrospective Case Series Comparing ROCK-I vs. Hypertonic Sodium Chloride for Post-Surgical Adjuvant Therapy.

    Cohen E, Din N, Aldrees S, et al.

    Journal of clinical medicine 2025; (14(5)) doi:10.3390/jcm14051512.

    PMID: 40095027
  8. 8

    Descemet's stripping without endothelial keratoplasty.

    Garcerant D, Hirnschall N, Toalster N, et al.

    Current opinion in ophthalmology 2019; (30(4)):275-285 doi:10.1097/ICU.0000000000000579.

    PMID: 31033737
  9. 9

    Descemet Stripping Only for a Chronic Descemet Detachment After Cataract Surgery.

    Hirabayashi KE, Mark D, Lau J, Lin CC

    Cornea 2020; (39(3)):379-381 doi:10.1097/ICO.0000000000002195.

    PMID: 31725698
  10. 10

    Therapeutic Potential of Rho Kinase Inhibitors in Corneal Disease: A Systematic Review of Preclinical and Clinical Studies.

    Ghenciu LA, Andrei D, Borza C, et al.

    Biomedicines 2025; (13(7)) doi:10.3390/biomedicines13071602.

    PMID: 40722674
  11. 11

    Surgical Management of Fuchs Endothelial Corneal Dystrophy: A Treatment Algorithm and Individual Patient Meta-Analysis of Descemet Stripping Only.

    Din N, Cohen E, Popovic M, et al.

    Cornea 2022; (41(9)):1188-1195 doi:10.1097/ICO.0000000000002975.

    PMID: 35942547
  12. 12

    Use of Topical Rho Kinase Inhibitors in the Treatment of Fuchs Dystrophy After Descemet Stripping Only.

    Macsai MS, Shiloach M

    Cornea 2019; (38(5)):529-534 doi:10.1097/ICO.0000000000001883.

    PMID: 30720541
  13. 13

    Medium-Term Failure of Descemet's Stripping Only and Fuchs' Dystrophy With Pancorneal Guttae.

    Arsiwalla T, Trinh T, Goolam S, et al.

    Cornea 2022; (41(8)):1064-1067 doi:10.1097/ICO.0000000000002873.

    PMID: 35830584
  14. 14

    Comparative Analysis of Descemet Membrane Endothelial Keratoplasty (DMEK) Versus Descemetorhexis Without Keratoplasty (DSO) in Patients with Fuchs Endothelial Corneal Dystrophy.

    Díaz-Mesa V, Sánchez-Ventosa Á, González-Cruces T, et al.

    Journal of clinical medicine 2025; (14(14)) doi:10.3390/jcm14144857.

    PMID: 40725557
  15. 15

    Functional Evaluation of Two Corneal Endothelial Cell-Based Therapies: Tissue-Engineered Construct and Cell Injection.

    Peh GSL, Ong HS, Adnan K, et al.

    Scientific reports 2019; (9(1)):6087 doi:10.1038/s41598-019-42493-3.

    PMID: 30988373
  16. 16

    Biomaterials for corneal endothelial cell culture and tissue engineering.

    Parekh M, Romano V, Hassanin K, et al.

    Journal of tissue engineering 2021; (12()):2041731421990536 doi:10.1177/2041731421990536.

    PMID: 33643603
  17. 17

    Corneal endothelial cell dysfunction: etiologies and management.

    Feizi S

    Therapeutic advances in ophthalmology 2018; (10()):2515841418815802 doi:10.1177/2515841418815802.

    PMID: 30560230
  18. 18

    Regenerative Therapy for Fuchs Endothelial Corneal Dystrophy.

    Soh YQ, Mehta JS

    Cornea 2018; (37(4)):523-527 doi:10.1097/ICO.0000000000001518.

    PMID: 29384808
  19. 19

    Optimisation of Storage and Transportation Conditions of Cultured Corneal Endothelial Cells for Cell Replacement Therapy.

    Wahlig S, Peh GSL, Adnan K, et al.

    Scientific reports 2020; (10(1)):1681 doi:10.1038/s41598-020-58700-5.

    PMID: 32015414
  20. 20

    Comprehensive combined analysis of physician-initiated phase II and III clinical trials on a cultured human corneal endothelial cell product for treating bullous keratopathy.

    Ueno M, Imai K, Tomioka Y, et al.

    Japanese journal of ophthalmology 2024; (68(6)):660-668 doi:10.1007/s10384-024-01123-w.

    PMID: 39356386
  21. 21

    Quality of life after cultured corneal endothelial cell transplant in patients with bullous keratopathy.

    Yamamoto Y, Tomioka Y, Numa K, et al.

    Japanese journal of ophthalmology 2025; doi:10.1007/s10384-025-01280-6.

    PMID: 40952553
  22. 22

    Rho kinase inhibitor enables cell-based therapy for corneal endothelial dysfunction.

    Okumura N, Sakamoto Y, Fujii K, et al.

    Scientific reports 2016; (6()):26113 doi:10.1038/srep26113.

    PMID: 27189516
  23. 23

    Human Corneal Endothelial Cell Cultivation From Old Donor Corneas With Forced Attachment.

    Parekh M, Ahmad S, Ruzza A, Ferrari S

    Scientific reports 2017; (7(1)):142 doi:10.1038/s41598-017-00209-5.

    PMID: 28273942
  24. 24

    Early Clinical Outcomes of Cultured Human Corneal Endothelial Cell Injection (Vyznova) for Bullous Keratopathy: Initial Clinical Experience.

    Kobayashi A, Mori N, Yokogawa H, et al.

    Cornea 2025; doi:10.1097/ICO.0000000000003984.

    PMID: 40903103
  25. 25

    Heterozygous Tcf4 Deficiency Mitigates Fuchs Endothelial Corneal Dystrophy Progression in a Mouse Model.

    Ito S, Oyama Y, Yuasa T, et al.

    Investigative ophthalmology & visual science 2025; (66(4)):19 doi:10.1167/iovs.66.4.19.

    PMID: 40197778
  26. 26

    Dysregulation of the TCF4 Isoform in Corneal Endothelial Cells of Patients With Fuchs Endothelial Corneal Dystrophy.

    Honda T, Nakagawa T, Yuasa T, et al.

    Investigative ophthalmology & visual science 2024; (65(6)):27 doi:10.1167/iovs.65.6.27.

    PMID: 38884552
  27. 27

    Genetic mutations and molecular mechanisms of Fuchs endothelial corneal dystrophy.

    Liu X, Zheng T, Zhao C, et al.

    Eye and vision (London, England) 2021; (8(1)):24 doi:10.1186/s40662-021-00246-2.

    PMID: 34130750
  28. 28

    Generation of TGFBI knockout ABCG2+/ABCB5+ double-positive limbal epithelial stem cells by CRISPR/Cas9-mediated genome editing.

    Kim EK, Kim S, Maeng YS

    PloS one 2019; (14(2)):e0211864 doi:10.1371/journal.pone.0211864.

    PMID: 30753226
  29. 29

    Proteomic profiling of TGFBI-null mouse corneas reveals only minor changes in matrix composition supportive of TGFBI knockdown as therapy against TGFBI-linked corneal dystrophies.

    Poulsen ET, Runager K, Nielsen NS, et al.

    The FEBS journal 2018; (285(1)):101-114 doi:10.1111/febs.14321.

    PMID: 29117645
  30. 30

    Start codon disruption with CRISPR/Cas9 prevents murine Fuchs' endothelial corneal dystrophy.

    Uehara H, Zhang X, Pereira F, et al.

    eLife 2021; (10()).

    PMID: 34100716
  31. 31

    Trinucleotide Repeat-Targeting dCas9 as a Therapeutic Strategy for Fuchs' Endothelial Corneal Dystrophy.

    Rong Z, Gong X, Hulleman JD, et al.

    Translational vision science & technology 2020; (9(9)):47 doi:10.1167/tvst.9.9.47.

    PMID: 32934897
  32. 32

    TGFBI R124H mutant allele silencing in granular corneal dystrophy type 2 using topical siRNA delivery.

    McLain A, Kowalczyk A, Baran-Rachwalska P, et al.

    Journal of controlled release : official journal of the Controlled Release Society 2025; (382()):113681 doi:10.1016/j.jconrel.2025.113681.

    PMID: 40185334

This page provides educational information about emerging treatments and gene therapies for corneal dystrophy. Always consult your ophthalmologist to discuss the best proven treatment options for your specific vision needs.

Get notified when new evidence is published on Corneal dystrophy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.